190A — Chordia Therapeutics Share Price
Last trade - 00:00- ¥11bn
- ¥8bn
- ¥3bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.69 | ||
| Price to Tang. Book | 2.69 | ||
| Price to Free Cashflow | 18.35 | ||
| Price to Sales | 3.99 | ||
| EV to EBITDA | 28.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.73% | ||
| Return on Equity | 5.6% | ||
| Operating Margin | 8.48% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | n/a | n/a | n/a | n/a | 2,500 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chordia Therapeutics Inc is a Japan-based drug discovery venture company mainly engaged in the research and development of novel anticancer drugs for commercialization. The Company's main business is the research and development of small molecule breakthrough drugs (first-in-class) with novel actions in the field of oncology, where there is a high unmet medical need. The Company concentrates on management and research operations (exploratory, preclinical, and clinical research), particularly in the discovery, evaluation, optimization, and clinical testing of candidate compounds, and outsources basic research, active pharmaceutical ingredient and drug product manufacturing, distribution, and sales to its various external partners to advance its business.
Directors
- Last Annual
- August 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- October 12th, 2017
- Public Since
- June 14th, 2024
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 65,543,800
- Address
- 2-26-1, Muraoka-Higashi, FUJISAWA-SHI, 251-0012
- Web
- https://www.chordiatherapeutics.com/
- Phone
- +81 366619543
- Auditors
- KPMG AZSA LLC
Similar to 190A
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
As of Today at 19:59 UTC, shares in Chordia Therapeutics are trading at ¥152. This share price information is delayed by 15 minutes.
Shares in Chordia Therapeutics last closed at ¥152 and the price had moved by over the past 365 days. In terms of relative price strength the Chordia Therapeutics share price has matched the Nikkei 225 Index by over the past year.
There is no consensus recommendation for this security.
Chordia Therapeutics does not currently pay a dividend.
Chordia Therapeutics does not currently pay a dividend.
Chordia Therapeutics does not currently pay a dividend.
To buy shares in Chordia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥152, shares in Chordia Therapeutics had a market capitalisation of ¥10bn.
Here are the trading details for Chordia Therapeutics:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 190A
Based on an overall assessment of its quality, value and momentum Chordia Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chordia Therapeutics. Over the past six months, its share price has matched the Nikkei 225 Index by .
As of the last closing price of ¥152, shares in Chordia Therapeutics were trading -5.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Chordia Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥152.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Chordia Therapeutics' directors